Narain Meditech Retailers Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -4.18%
(FY 2020)
- Profit -34.30%
(FY 2020)
- Ebitda 82.99%
(FY 2020)
- Net Worth 61.64%
(FY 2020)
- Total Assets -3.77%
(FY 2020)
About Narain Meditech Retailers
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mridula Shukla, Shyam Keshari, and Pradeep Kumar serve as directors at the Company.
- CIN/LLPIN
U74120UP2012PTC053176
- Company No.
053176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Varanasi, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Narain Meditech Retailers?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mridula Shukla  | Managing Director | 19-Oct-2012 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shyam Keshari | Director | 19-Oct-2012 | Current |
| Pradeep Kumar | Director | 19-Oct-2012 | Current |
Financial Performance of Narain Meditech Retailers.
Narain Meditech Retailers Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 4.18% decrease. The company also saw a substantial fall in profitability, with a 34.3% decrease in profit. The company's net worth Soared by an impressive increase of 61.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Narain Meditech Retailers?
In 2019, Narain Meditech Retailers had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Narain Meditech Private LimitedActive 13 years
Mridula Shukla, Shyam Keshari and 1 more are mutual person
- Narain Bio Sciences Private LimitedActive 12 years 1 month
Mridula Shukla, Shyam Keshari and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Narain Meditech Retailers?
Unlock and access historical data on people associated with Narain Meditech Retailers, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Narain Meditech Retailers, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Narain Meditech Retailers's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
